

How UKTI Can Help Your Business

UKTI Life Science Investment Organisation (LSIO)

UKTI has established a dedicated unit, the LSIO, to act as your interface with the UK life science sector. The LSIO is your guide to identifying research, development and delivery partners and will support you through every step of investing in and working in the UK. Dr Mark Treherne, CEO of the UKTI LSIO and his team work closely with you to understand your needs and requirements, partnering you with the right people in the UK.

For further information please contact UK Trade & Investment at

enquiries@ukti-invest.com or visit us at:
www.ukti.gov.uk/lifesciences




To find out more,
scan this code with
your smart phone.
www.ukti.gov.uk
+44(0)20 7215 5000

UK Trade & Investment is the Government Department that helps UK-based companies succeed in the global economy. We also help overseas companies bring their high-quality investment to the UK's dynamic economy acknowledged as Europe's best place from which to succeed in global business.

UK Trade & Investment offers expertise and contacts through its extensive network of specialists in the UK, and in British embassies and other diplomatic offices around the world. We provide companies with the tools they require to be competitive on the world stage.

Part of the UK Government's portfolio of Solutions for Business




Unlock your Global Business Potential: Addressing the Dementia Challenge

UKTI Life Science Investment Organisation

www.ukti.gov.uk/lifesciences

Market Opportunity



Dementia currently **costs the UK economy \$37 billion per year*** more than cancer and heart disease combined. Currently there are **800,000 people living with dementia in the UK**, in less than 10 years this will be 1 million*. The total estimated worldwide cost of dementia care is currently \$600 billion, 1% of the world's GDP**.

Given the projected increase in the number of people who will be diagnosed with dementia, current and expected costs, and devastating consequences, UK Prime Minister David Cameron launched the Prime Minister's **Challenge on Dementia**. This focuses on: 1) Boosting dementia research by increasing funding and mobilising the UK's world-class specialist facilities and strengths in neuroscience; 2) Driving improvements in the way people with dementia are diagnosed, treated and cared for; and 3) Making communities more dementia-friendly.


The Prime Minister's Challenge on Dementia will work to identify patients with early indications of the symptoms of dementia via more sophisticated **diagnostics**, which will enable a step-change in the way in which **dementia disease modifying therapies** and interventions are tested. The UK will also work to invest in improving **symptomatic relief** and **assisted living technologies** so that people can live well with dementia.

* Alzheimer's Society
 **Alzheimer's Disease International

Ease of Doing Business

The UK Government continues to improve the UK business environment by incentivising innovation:

- **Low corporation tax rate, dropping to 21%** by April 2014
- **Patent Box reduces corporation tax to 10%** on profits from UK patents
- **Up to 27p back per £1 spent** with the R&D tax credits
- **£180 million** Biomedical Catalyst to fund translation and commercialisation of up to 90 life sciences projects
- Aim to **double current funding** levels on dementia research by 2015



Rich Diverse Ecosystem



The UK dementia ecosystem is underpinned by data to drive your discovery through to delivery of care

Leading research funders and charities support research and patient engagement


- **Medical Research Council (MRC)** funds studies to better understand causes of dementia
- **Wellcome Trust** initiative in neurodegenerative diseases with MRC
- **Alzheimer's Research UK** funds the most promising dementia research
- **Alzheimer's Society** supports a Drug Discovery Programme
- **Technology Strategy Board** stimulates technology enabled innovation and assisted living

World-class researchers lead thinking on dementia disease biology and intervention

UK researchers have deep expertise in: Neurobiology, Drug discovery, Biomarker discovery, Stem cells, Genetics and Omics, Cognitive Neuroscience, Imaging and Informatics.

Data resources to enable research


- **UK Biobank** resource of 500,000 volunteers with biosamples, clinical records, and patient histories. Pilots of imaging and genome sequencing
- **UK Brain Banks Network** provides high quality brain tissue to scientists and clinicians
- **National Centre for Mental Health, Wales** working on improving the understanding of mental health genetics and treatment



Infrastructure and specialist clinical networks support translation and access to patients

- **National Institute for Health Research (NIHR)** Dementia Translational Research Collaboration streamlines your interface with dementia focused Biomedical Research Units and Centres across the UK
- **Academic Health Science Centres** link universities, industry, and the NHS to develop technologies into health products and services
- **Enabling Research In Care Homes (ENRICH)** supports real-world studies

Map of dementia clinical research networks across the UK



Data to drive clinical translation

- **Clinical Practice Research Datalink** supports research and clinical trial feasibility
- **NIHR BioResource** enables recall of existing cohorts by genotype and phenotype

Robust regulatory and health technology assessments ensure portability of your products across the world


- **Medicines and Healthcare products Regulatory Agency (MHRA)** and **European Medicines Agency (EMA)** are globally-respected regulators. The UK also has an expert working group to consider innovative regulation
- **National Institute for Health and Clinical Excellence (NICE)** provides world-class health technology assessments

Single NHS access points facilitate uptake and diffusion of your products and services to patients

- **Academic Health Science Networks** will facilitate adoption and dissemination of innovation into the NHS
- **NIHR Collaborations for Leadership in Applied Health Research and Care** support the translation of research evidence into practice

Anonymised data to deliver and monitor real-world outcomes

- **Clinical Practice Research Datalink** enables post-market surveillance
- **Hospital Episode Statistics (HES)** provides anonymised data on hospital admissions, outpatient appointments and A&E attendance in England
- **Health and Social Care Information Centre** collect and make available national data from a range of health and care organisations



Market Success

Join other international and UK businesses working with the UK to improve dementia R&D, diagnosis, treatment and care

1 Eli Lilly invests in UK Neuroscience

Over the last decade Eli Lilly has invested more than £100 million in its Surrey research centre, home to much of the company's neuroscience research and a new early-stage facility with 130 scientists working across disciplines such as clinical pharmacology, PK/PD, statistics and data sciences. This global company has invested in the UK due to the UK's academic strengths and collaborative opportunities in neuroscience. In 2010, Eli Lilly established the Centre for Cognitive Neuroscience which brings together a consortium of Eli Lilly scientists with world leading academics from six British universities, and aims to improve the probability of clinical success for molecules targeting the symptoms of cognitive decline in schizophrenia, Alzheimer's and Parkinson's disease.

2 IXICO and Cambridge Cognition combine brain imaging with computer-based tests to improve dementia diagnosis

A collaborative project led by IXICO is developing a novel, cost-effective digital healthcare system to enable earlier diagnosis in dementia. The system will be deployed in a memory clinic or a local brain health centre and will combine computerised cognitive testing and quantitative brain imaging, aiming to provide doctors with a quality of information currently available only in highly specialist centres.

The project was awarded funding from the government funded Biomedical Catalyst in 2012.



In medical imaging, and in the clinical aspects of medical imaging, the UK is especially strong. We have on our doorstep world experts we can engage as consultants, and bright scientists and research groups developing new technologies. The NHS structures are rapidly evolving to make it a superb platform for assessing new technology, and combined with health economic expertise, the UK can help us demonstrate the value of our technology in a way that can help translate to larger global markets.

Derek Hill, Founder and CEO, IXICO

